REMARKS

Claims 1-6 were pending in the present application. Claims 1-3 and 5 were rejected. Claim 1 is herein amended. Claims 2-4 and 6 are herein cancelled without prejudice.

Information Disclosure Statement

The Office Action states that citations in the September 28, 2007 IDS that have been cited in prior IDS's have been lined-through. The "Damioan" document and the Cicala document are lined through, and a note stating "Duplicate. Do not print" is included. However, although the Cicala document appears to be a duplicate, this does not appear to be true of the "Damioan" document. In the September 28, 2007 IDS, the following document is cited:

> DAMIOAN BRUCE P ET AL.: "Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 288, no. 2, February 1999, pages 671-678.

However, in the September 30, 2003 IDS, the following document is cited:

> Damiano, Bruce P., et al. "Increased Expression of Protease Activated Receptor-2 (PAR-2) in Balloon-Injured Rat Cartotid Artery." *Thromb Haemost* 1999; 81: 808-14.

Although these references are both co-authored by Bruce P. Damiano (the September 28, 2007 includes a typographical error misspelling the author's name), these references are not duplicates of each other. Applicants respectfully request that the Examiner provide a supplemental initialed SB/08 form in which the "Damioan" document submitted on September 28, 2007 is not lined through and is initialed.

Applicants' Response to Claim Rejections under 35 U.S.C. §112

Claims 1-3 and 5 were rejected under 35 U.S.C. §112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to make and/or use the invention.

The Office Action states that while the specification is enabling for methods using PAR-2 agonists to treat rapidly-progressive glomerulonephritis as well as crescentic glomerulonephritis, it does not reasonably provide enablement for use of PAR-2 agonists to treat other kidney diseases. The Office Action acknowledges that the specification provides a nexus between the PAR-2 receptor and glomerulonephritis, and that the PAR-2 ligands are protective of the specific damage produced by destruction of the glomerular basement membrane.

Accordingly, in order to overcome the pending rejection, Applicants herein amend claim 1 to incorporate the subject matter of claim 4, which recites treatment of rapidly progressive glomerulonephritis syndrome or crescentic (extratubular) glomerulonephritis. Applicants respectfully submit that, since this subject matter was previously presented, this amendment does not raise new issues requiring further search or consideration.

Allowable Subject Matter

The Office Action indicates that claim 4 is objected to for depending from a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. As noted above, Applicants herein incorporate the allowable subject matter of claim 4 into claim 1. Additionally, Applicants herein cancel

withdrawn claim 6. Thus, Applicants respectfully submit that the application is in condition for allowance.

For at least the foregoing reasons, the claimed invention distinguishes over the cited art and defines patentable subject matter. Favorable reconsideration is earnestly solicited.

Should the Examiner deem that any further action by applicants would be desirable to place the application in condition for allowance, the Examiner is encouraged to telephone applicants' undersigned attorney.

If this paper is not timely filed, Applicants respectfully petition for an appropriate extension of time. The fees for such an extension or any other fees that may be due with respect to this paper may be charged to Deposit Account No. 50-2866.

Respectfully submitted,

WESTERMAN, HATTORI, DANIELS & ADRIAN, LLP



Ryan B. Chirnomas
Attorney for Applicants
Registration No. 56,527
Telephone: (202) 822-1100
Facsimile: (202) 822-1111

RBC/nrp